Table 1 Characteristics of the total study population and individuals with and without the Metabolic Syndrome
Risk factor/Trait | All (n = 35,869) | Without MetS* (n = 25,961) | With MetS* (n = 7,122) | |||
|---|---|---|---|---|---|---|
Men | Women | Men | Women | Men | Women | |
N (%) | 13,942 (38.9) | 21,927 (61.1) | 9,452 (36.4) | 16,509 (63.6) | 3,168 (44.5) | 3,954 (55.5) |
Age (years), mean ± SD | 53.0 ± 15.8 | 50.9 ± 16.2 | 50.9 ± 16.3 | 48.1 ± 15.9 | 58.8 ± 12.9 | 60.5 ± 13.9 |
Weight (kg), mean (±SD) | 86.2 ± 14.9 | 71.9 ± 15.2 | 81.7 ± 12.2 | 68.3 ± 13.1 | 97.1 ± 15.3 | 84.5 ± 15.9 |
Body Mass Index (%) | ||||||
≤25 kg/m2 | 29.7 | 46.4 | 40.4 | 57.9 | 4.3 | 8.0 |
25 - <30 kg/m2 | 45.6 | 30.3 | 47.7 | 28.9 | 38.6 | 33.1 |
≥30 kg/m2 | 24.7 | 23.3 | 11.9 | 13.1 | 57.1 | 58.9 |
Waist circumference (cm), mean ± SD | 98.8 ± 13.0 | 86.8 ± 14.3 | 94.1 ± 10.9 | 82.5 ± 12.0 | 110.4 ± 10.7 | 101.6 ± 11.8 |
Blood parameters | ||||||
Blood glucose (mmol/l), mean ± SD | 5.7 ± 2.0 | 5.3 ± 1.6 | 5.2 ± 1.4 | 4.9 ± 0.9 | 7.1 ± 2.9 | 6.7 ± 2.6 |
Total Cholesterol (mmol/l), mean ± SD | 5.3 ± 1.1 | 5.4 ± 1.1 | 5.2 ± 1.0 | 5.3 ± 1.0 | 5.3 ± 1.2 | 5.6 ± 1.1 |
HDL (mmol/l), mean ± SD | 1.4 ± 0.4 | 1.7 ± 0.4 | 1.5 ± 0.4 | 1.8 ± 0.4 | 1.2 ± 0.3 | 1.4 ± 0.4 |
LDL (mmol/l), mean ± SD | 3.3 ± 0.9 | 3.3 ± 0.9 | 3.3 ± 0.9 | 3.2 ± 0.9 | 3.3 ± 1.0 | 3.5 ± 1.0 |
Triglycerides (mmol/l), median(Q1; Q3) | 1.6 (1.1;2.4) | 1.3 (0.9;1.9) | 1.4 (1.0;1.9) | 1.2 (0.9;1.5) | 2.4 (1.7;3.4) | 2.1 (1.6;2.9) |
Blood Pressure (BP) | ||||||
Systolic BP (mmHg), mean ± SD | 133.6 ± 18.2 | 128.5 ± 19.3 | 129.9 ± 17.4 | 124.4 ± 17.9 | 142.7 ± 16.8 | 142.7 ± 17.5 |
Diastolic BP (mmHg), mean ± SD | 81.4 ± 10.4 | 79.2 ± 10.6 | 79.9 ± 10.0 | 77.6 ± 10.2 | 84.9 ± 10.5 | 84.5 ± 10.4 |
Smoking status (%) | ||||||
Current Smoker | 27.5 | 23.5 | 28.7 | 24.6 | 23.7 | 18.9 |
Past Smoker | 39.8 | 22.3 | 35.4 | 22.4 | 50.3 | 21.6 |
Never Smoker | 32.8 | 54.2 | 35.9 | 53.0 | 26.0 | 59.5 |
MetS Traits (%) | ||||||
WC | 36.4 | 41.5 | 17.1 | 26.3 | 84.1 | 92.8 |
TG | 24.0 | 12.9 | 12.1 | 4.6 | 63.7 | 53.4 |
HDL | 12.2 | 13.9 | 4.6 | 5.6 | 32.8 | 46.8 |
BP | 66.6 | 52.9 | 55.8 | 41.8 | 92.5 | 91.6 |
GL | 29.5 | 17.6 | 13.1 | 5.3 | 75.6 | 68.1 |
Pharmacotherapy (%) | ||||||
Anti-diabetic | 12.0 | 7.0 | 4.9 | 1.6 | 34.2 | 30.1 |
Anti-hypertensive | 41.7 | 34.2 | 32.3 | 25.0 | 67.3 | 67.8 |
Lipid lowering | 18.1 | 10.5 | 14.0 | 6.9 | 29.5 | 24.6 |
Comorbidities (%) | ||||||
Cardiovascular diseases | 20.5 | 10.5 | 16.5 | 7.2 | 31.7 | 22.9 |
Cancer | 5.5 | 4.9 | 5.2 | 4.3 | 6.7 | 7.1 |